Citations

Showing 10 of 108104 citations.

NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial
Mayo, Marlyn J. , Wigg, Alan , Leggett, Barbara , Arnold, Hays, Thompson, Alexander , Weltman, Martin , Carey, Elizabeth J. , Ling, Lei , Rossi, Stephen J., DePaoli, Alex M. , Muir, Andrew Joseph , Rossi, Stephen J.

Mayo Clinic

Hepatology Communications | August 30, 2018 | Volume: 2 | Issue: 9 | Pages: 1037-1050

10.1002/hep4.1209 | PMID 30202819 Get It

Patients with primary biliary cholangitis (PBC) who had an inadequate response to ursodiol have few treatment options. Alkaline phosphatase (ALP) and bilirubin levels correlate with the risk of liver transplant or death in PBC patients. Fibroblast growth factor (FGF) 19 is a hormone that acts directly in the liver to regulate bile acid synthesis. We evaluated NGM282, an engineered analogue of FGF19, for the treatment of PBC. In this 28‐day, double‐blind, placebo‐controlled phase 2 trial, 45 PBC patients who had an inadequate response to ursodiol were randomly assigned 1:1:1 to receive subcutaneous daily doses of either NGM282 at 0.3 mg (n = 14), 3 mg (n = 16), or placebo (n = 15). The primary endpoint was a change in ALP from baseline after 28 days of treatment. At day 28, ALP was significantly reduced with NGM282 treatment at both 0.3 mg (least‐squares mean –51.0 IU/L [standard error (SE) 15.4]) and 3 mg (–66.0 IU/L [SE 16.0]) versus placebo (3.3 IU/L [SE 14.8]), with least‐squares mean differences of –54.3 IU/L (95% confidence interval –104.2 to –4.5; P = 0.0149) and –69.3 IU/L (95% confidence interval –120.5 to –18.3; P = 0.0030), respectively. Fifty percent (7 of 14) of patients receiving NGM282 0.3 mg and 46% (6 of 13) of those receiving NGM282 3mg achieved 15% or greater reduction in ALP levels from baseline, compared with 7% (1 of 15) of patients receiving placebo. NGM282 also significantly reduced serum concentrations of transaminases and immunoglobulins. Most adverse events were grade 1 (mild) to grade 2 (moderate) in severity, with gastrointestinal disorders more frequent in the NGM282 treatment groups. No worsening of pruritus was observed with NGM282 treatment. Conclusion: NGM282 administered for 28 days resulted in significant improvements in ALP and transaminase levels compared with placebo, with an acceptable safety profile in patients with PBC. (Hepatology Communications 2018; 00:000‐000)
Preoperative Planning Using 3-Dimensional Printing for Complex Paraspinal Schwannoma Resection: 2-Dimensional Operative Video
Stone, Jonathan J. , Matsumoto, Jane M., Spinner, Robert J. , Morris, Jonathan M.

Mayo Clinic

Operative Neurosurgery | August 30, 2018 | Volume: 16 | Issue: 3 | Pages: E80-E80

10.1093/ons/opy239 | PMID 30169700 Get It

Abstract Schwannomas are benign peripheral nerve sheath tumors that are typically round, smooth, and straightforward to resect. Occasionally they are more complicated to resect because of their size, location, degree of bony erosion, and vascular or neural compression. These complex lesions frequently require multidisciplinary surgical teams in order to decrease surgical morbidity. Historically, surgical planning consisted of imaging review and verbal communication among team members. 3-dimensional (3D) printing offers a new method for preoperative planning and is becoming more popular in Neurosurgery. This video demonstrates the use of 3D printing for complex paraspinal tumors in the cervical, thoracic, and sacral regions. The Institutional Review Board Office for Human Research Protection does not require approval for single participant case studies, or a case series with multiple participants. The subjects involved in this study were not identifiable and the general surgical consent form included permission for intraoperative photos.
P6473Is carotid plaque shear wave elastography a marker of plaque vulnerability? Association with cardiovascular events and duration of statin therapy
DeMarco, J. Kevin , Huston, John , Brinjikji, Waleed , Macedo, Túlio Augusto Alves , Dailey, Eric J. , Hagen, Mary E., Huang, Rongchong , Urban, Matthew W. , Macedo, T A, Pellikka, Patricia A. , Mulvagh, Sharon L.

Mayo Clinic

European Heart Journal | August 30, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy566.p6473 Get It

1344Myocardial bridging is associated with coronary endothelial dysfunction in patients with chest pain and non-obstructive coronary artery disease
Sara, Jaskanwal Deep Singh , Prasad, Megha , Lerman, Lilach O. , Corban, Michel , Widmer, R. Jay , Lerman, Amir

Mayo Clinic

European Heart Journal | August 30, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy565.1344 Get It

P619Incident premature coronary heart disease in women: an analysis of 53 biomarkers from the Women's Health Study
Moorthy, M. Vinayaga , Glynn, Robert, Dugani, Sagar B. , Demler, Olga , Ridker, Paul M. , Mora, Samia

Mayo Clinic

European Heart Journal | August 30, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy564.p619 Get It

5921Premature ventricular contraction-triggered ventricular fibrillation: an under-recognized mechanism of sudden cardiac arrest in the young
Giudicessi, John R. , Kappa, S, Cannon, Bryan C. , Ackerman, Michael J. , Noseworthy, Peter A. , McLeod, Christopher J. , Asirvatham, Samuel J.

Mayo Clinic

European Heart Journal | August 30, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy566.5921 Get It

P298Safety of catheter-free VT ablation: Dose-dependent LVEF changes after proton beam therapy of the LV in a porcine model
Deisher, A., Suzuki, Akihiro , Kruse, Jon J. , Parker, Katrina, Newman, Laura K. , Herman, Michael , Packer, Douglas L. , Hohmann, Stephan , Konishi, Hiroki , Rettmann, Maryam E. , Lehmann, H. Immo

Mayo Clinic

European Heart Journal | August 30, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy564.p298 Get It

Testosterone Therapy: Do American and European Clinicians Have Different Approaches?
Trost, Landon , Zitzmann, Michael

Mayo Clinic

The Journal of Sexual Medicine | August 30, 2018 | Volume: 15 | Issue: 10 | Pages: 1373-1377

10.1016/j.jsxm.2018.07.010 | PMID 30174267 Get It